Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Dual GIP and GLP-1 receptor agonists
7 evidence topics · 7 sources
Tirzepatide: FDA-approved indications
Tirzepatide: dosage escalation and maintenance dosages
Tirzepatide: three-year weight change and progression to type 2 diabetes in participants with prediabetes
“At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: apnea-hypopnea index in moderate-to-severe obstructive sleep apnea in SURMOUNT-OSA
“In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: oral hormonal contraceptive counseling in the American Diabetes Association 2026 Standards of Care
“Tirzepatide in particular may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, an effect that is largest after the first dose and diminishes over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals using oral hormonal contraceptives should switch to a nonoral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: self-pay price for the KwikPen and single-dose vial
Tirzepatide: average wholesale price and National Average Drug Acquisition Cost
| Medication | Typical adult maintenance dose | AWP for 30-day supply | NADAC for 30-day supply |
|---|---|---|---|
| Tirzepatide | “5, 10, or 15 mg once weekly”View highlighted excerpt for this quote | “$1,304”View highlighted excerpt for this quote | “$1,022”View highlighted excerpt for this quote |